What is Microvisk?
Based in Oxford, UK, Microvisk Technologies is a specialized medical device manufacturer focused on the critical field of anticoagulation monitoring. The company distinguishes itself through the application of patented Micro Electro Mechanical Sensors (MEMS) technology, which powers its CoagMax PT/INR System. This innovation facilitates high-accuracy, point-of-care testing, effectively bridging the gap between clinical laboratory standards and the convenience of at-home monitoring for patients on anticoagulant therapy. As an ISO 13485:2016 accredited entity, Microvisk maintains a rigorous commitment to quality and regulatory compliance, serving both healthcare professionals and individual patients who require precise, real-time diagnostic data to manage their health outcomes effectively.
How much funding has Microvisk raised?
Microvisk has raised a total of $22.9M across 3 funding rounds:
Series A
$3.9M
Series B
$9.5M
Series C
$9.5M
Series A (2010): $3.9M with participation from Oxford Technology Management and Finance Wales
Series B (2011): $9.5M led by Oxford Technology and New Hill Management
Series C (2011): $9.5M, investors not publicly disclosed
Key Investors in Microvisk
Oxford Technology Management
A venture firm specializing in SEIS and EIS funds that provide private investors with access to high-growth technology startups, with a particular focus on the Oxford innovation ecosystem.
Finance Wales
A government-backed financial institution providing sustainable business finance, including equity and loans, to support economic growth and technology ventures within Wales.
New Hill Management
An investment management firm that provides strategic capital and operational guidance to emerging growth companies, focusing on long-term value creation.
What's next for Microvisk?
With the recent infusion of capital, Microvisk is strategically positioned to enhance its market penetration and refine its diagnostic product pipeline. The focus will likely shift toward scaling manufacturing capabilities to meet the growing demand for point-of-care testing solutions. Furthermore, the company is expected to leverage this financial backing to strengthen its clinical validation studies and expand its distribution networks. By maintaining its focus on MEMS-based innovation, Microvisk aims to solidify its role as a key player in the global medical device landscape, potentially exploring new therapeutic areas where its sensor technology can provide significant clinical value and improve patient quality of life.
See full Microvisk company page
